An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases

Ophthalmic Epidemiology

Volumn 15, Issue 2, 2008, Pages 76-83

  Kymes, Steven M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness analysis; Cost utility analysis; Decision analysis; Glaucoma macular degeneration; Health economics; Ophthalmology

Indexed keywords

PHOTOSENSITIZING AGENT; VASCULOTROPIN ANTIBODY;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; GLAUCOMA; HEALTH CARE POLICY; HEALTH PROGRAM; INTRAOCULAR HYPERTENSION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RETINA MACULA DEGENERATION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VISUAL IMPAIRMENT;

COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; GLAUCOMA, OPEN-ANGLE; HUMANS; MACULAR DEGENERATION; MODELS, ECONOMIC; OCULAR HYPERTENSION; VISION DISORDERS;

EID: 42449119806     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286580801939346     Document Type: Article

References (49)

1. Anderson GF, Reinhardt UE, Hussey PS, Petrosyan V. It's the prices stupid: Why the United States is so different from other countries. Health Aff (Millwood). 2003;22:89-105.
2. OECD Health Data 2006 - Frequently Requested Data (Health Expenditures). Organization for Economic Cooperation and Development, 2006.
3. Baladi JF, Menon D, Otten N. Use of economic evaluation guidelines: 2 years' experience in Canada. Health Econ. 1998;7:221-7.
4. Drummond MF, Schulpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford: Oxford University Press, 2005.
5. Oliver A, Mossialos E, Robinson R. Health technology assessment and its influence on health-care priority setting. Int J Technol Assess Health Care. 2004;20:1-10.
6. Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110:2310-7.
7. Busbee BG, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109:606-12.
8. Brown GC, Brown MM, Campanella J, Beauchamp GR. The costutility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Ophthalmol. 2005;140:679-87.
9. Brown GC, Brown MM, Sharma S, et al. Value-based medicine and ophthalmology: An appraisal of cost-utility analyses. Trans Am Ophthalmol Soc. 2004;102:177-85; discussion 185-8.
10. Busbee BG, Brown GC, Brown MM. Cost-effectiveness of ocular interventions. Curr Opin Ophthalmol. 2003;14:132-8.
11. Brown MM, Brown GC, Sharma S, Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204-23.
12. Membreno JH, Brown MM, Brown GC, Sharma S, Beauchamp GR. A cost-utility analysis of therapy for amblyopia. Ophthalmology. 2002;109:2265-71.
13. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, Ocular Hypertension Treatment Study G. Management of ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2006;141:997-1008.
14. Brown MM, Brown GC, Sharma S. Value-based medicine and vitreoretinal diseases. Curr Opin Ophthalmol. 2004;15:167-72.
15. Busbee BG, Brown MM, Brown GC, Sharma S. CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina. 2003;23:279-87; quiz 443-4.
16. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.[see comment]. Ophthalmology. 2001;108:2051-9.
17. Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001;12:230-4.
18. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: Results of a patient-based cost-utility analysis. Curr Opin Ophthalmol. 2000;11:175-9.
19. Brown GC, Brown MM, Sharma S, Busbee B, Landy J. A cost-utility analysis of interventions for severe proliferative vitreoretinopathy. Am J Ophthalmol. 2002;133:365-72.
20. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473-511.
21. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:632 e1.
22. Ranibizumab (Lucentis) for macular degeneration. Med Lett Drugs Ther. 2006;48:85-6.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine, 1 ed. New York: Oxford University Press, 1996;425.
24. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 - Getting started.Med Decis Making. 1997;17:123-5.
25. Clegg JP, Guest JF, Lehman A, Smith AF. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006;13:263-74.
26. Gieser DK, Tracy Williams R, O'Connell W, et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: A US multisite retrospective study. J Glaucoma. 2006;15:419-25.
27. Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: Analyses based on visual field and physician's assessment. J Glaucoma. 2003;12:456-62.
28. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology. 2007;114:238-45.
29. Loncarek K, Brajac I, Filipovi T, Caljkusi-Mance T, Stalekar H. Cost of treating preventable minor ocular injuries in Rijeka, Croatia. Croat Med J. 2004;45:314-7.
30. Muralikrishnan R, Venkatesh R, Prajna NV, Frick KD. Economic cost of cataract surgery procedures in an established eye care centre in Southern India. Ophthalmic Epidemiol. 2004;11:369-80.
31. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: A conceptual framework and preliminary assessment. Cornea. 2004;23:751-61.
32. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration.Pharmacoeconomics. 2006;24:319-34.
33. Taylor HR, Pezzullo ML, Nesbitt SJ, Keeffe JE. Costs of interventions for visual impairment. Am J Ophthalmol. 2007;143:561-5.
34. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol. 1998;236:811-21.
35. Taylor HR. LXIII Edward Jackson Memorial Lecture: Eye care: Dollars and sense. Am J Ophthalmol. 2007;143:1-8.
36. Kenkel D. On valuing morbidity, cost-effectiveness analysis, and being rude. J Health Econ. 1997;16:769-57.
37. Lee BS, Kymes SM, Nease RF, Sumner W, Siegfried CJ, Gordon MO. The impact of anchor point on utilities for five common ophthalmic conditions. Ophthalmology. 2007;In Press.
38. Torrance GW, Feeny DH. Utilities and Quality Adjusted Life Years. Int J Technol Assess Health Care. 1989;5:559-75.
39. Torrance GW. Social preferences for health states:An empirical evaluation of three measurement techniques. Soc Sci Med. 1976;10:129-136.
40. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: A cost-effectiveness analysis.[see comment]. Arch Ophthalmol. 2003;121:108-12.
41. Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma patients' assessment of their visual function and quality of life.J Glaucoma. 2002;11:154-63.
42. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology. 1989;96:255-64.
43. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine.[see comment]. JAMA. 1996;276:1253-8.
44. Brown MM, Brown GC, Sharma S. Value-Based Medicine to Evidence-Based Medicine. Chicago: AMA Press, 2005.
45. Nease RF, Owens DK. Use of influence diagrams to structure medical decisions. Med Decis Making. 1997;17:263-75.
46. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2 - Building a tree. Med Decis Making. 1997;17:126-35.
47. Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics. 2006;24:1043-53.
48. Polsky D, Glick HA, Willke RJ, Schulman KA. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 1997;6:243-52.
49. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-87.